Ibio Inc IBIO

Healthcare Biotechnology

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

NYSEAM:IBIO - Post by User

Ibio Inc

Bullboard Posts

Post by monstapeakeon Oct 18, 2014 3:10pm

312 Views

Post# 23040780

cheap tag along inbp

If you are following the action with ibio with its big rise Friday, do diligence on inbp which owns some 1.7mil shares of ibio. stock is around $.20 but will move in proportion to the increase in ibio. Worse ebola news materializes, the more the sp will respond. Thank me with Canadian cider from BC. gracias to all, peake

Bullboard Posts

Mullen Group: Navigates market challenges towards success